From the Rats RantWhat's Doing PAA.asx - PharmAust LimitedI...

From the Rats Rant

What's Doing

PAA.asx - PharmAust Limited I recently caught up with my old fishing mate Sam Wright from the board of PharmAust Limited to discuss their recent Phase II clinical trial update and to see what else PAA has in store for 2021. PAA are currently trading at 9.8c with a market cap of circa $31m. PAA researches both human and animal therapeutics to provide optimal clinical outcomes, PharmAust specialises in repurposing marketed drugs to lower the risks and costs of treatment development. PAA's leading drug candidate is called Monepantel (MPL) and affects a biochemical pathway that influences cancer growth and neurodegenerative diseases. MPL is a registered drug that is already used in sheep, now the company plans on re-purposing it for both cancer and COVID-19. Just yesterday PAA released an update on its Phase IIb Clinical Trial in pet dogs with B Cell Lymphoma which has sent tails wagging. The highlights are: Monepantel blood plasma levels assessed from six dogs in the Phase IIb trial Current trial provides an indicative optimal plasma level and target therapeutic dose PharmAust will continue recruitment to obtain further supportive evidence for efficacy to support a Phase III registration trial The boys and girls in the lab have analysed the blood plasma data in the context of the previous trial, while referencing side effects and efficacy and has identified the optimal dosage. It’s quite extraordinary that in the space of two trials PAA have figured out the maximum and minimum dosage. This is unheard of and has effectively saved the company hundreds of thousands of dollars and months and months of more trials, it’s quite a coup I reckon after talking to big Sammy. PharmAust said it will crack on with the Phase IIb trial and will continue to increase recruitment numbers to gain sufficient information for a future Phase III trial. PharmAust’s Chairman, Dr Roger Aston stated, “This represents a material advance in optimising the treatment regimen for canine patients with B-Cell lymphoma and may have applicability to other anti-cancer treatments in companion animals and in humans. Cancer therapy is all about optimising efficacy and minimising adverse events and this is particularly important with aggressive late-stage cancers such a Stage 4/5B-Cell lymphoma. Yesterday Dr Roger Aston did a solid interview to accompany the announcement which I recommend you should tune into, you can find it on the link below: https://bit.ly/2Sb1Nak According to a recent reportthe global veterinary medicine market size was estimated at USD$29.2 billion in 2020 and is expected to expand at a rate of 7.4% from 2021 to 2028 as pet ownership becomes increasingly common and vet care becomes more accessible. Canine lymphoma is relatively common and represents approximately 20% of new cancer diagnoses in dogs. It is most common in middle-aged and older dogs and the treatment can cost tens of thousands of dollars with complete remission being rare. Earlier this month PharmAust received a $650k research and development (R&D) tax incentive refund after lodging an application with AusIndustry. The R&D Tax Incentive scheme is a program jointly administered by the Australian Taxation Office and AusIndustry, under which companies can receive up to a 43.5% refundable tax offset of eligible expenses on research and development activities. The capital would be used to forward the clinical trial programs in dogs and humans. Leiden University had also tested PAA's Monepantel & Monepantel Sulphone and generated data that they demonstrated antiviral activity against SARS-Cov-2. PharmAust had previously demonstrated MPL’s antiviral activity in two independent laboratories in Australia in both primate and non-primate cell cultures so this just added even more clarification that it works. I got clients that own it and hope they go much higher but as always DYOR like I do !!!